TIDMHIK
RNS Number : 6033O
Hikma Pharmaceuticals Plc
18 May 2018
Hikma Pharmaceuticals PLC
Voting Results of 2018 Annual General Meeting
LONDON, 18 May 2018 - Hikma Pharmaceuticals PLC (the "Company")
announces its Annual General Meeting ("AGM"), held at Sofitel St
James, 6 Waterloo Place, London SW1Y 4AN on 18 May 2018 commenced
at 10:00 am. All resolutions were duly passed by shareholders by
way of a poll. Resolutions 1 to 17 were passed as ordinary
resolutions and Resolutions 18 to 21 were passed as special
resolutions.
As previously announced, Dr. Ronald Goode retired from the Board
at the close of the AGM.
Copies of the resolutions dealing with special business passed
at the AGM have been submitted to the National Storage Mechanism
and will shortly be available for inspection at
www.morningstar.co.uk/uk/nsm
The total number of votes cast on the poll for each resolution
(the full text of the resolutions is detailed in the notice of the
AGM dated 28 March 2018) is set out below. The number of Ordinary
Shares in issue on 18 May 2018 was 240,940,604.
Resolution Votes % Votes % Total Withheld
For Against Cast
------------------------- ------------ ------- ----------- ------ ------------ ----------
1. To receive
the 2017 report
and accounts 196,394,230 99.96 72,200 0.04 196,466,430 245,708
------------------------- ------------ ------- ----------- ------ ------------ ----------
2. To approve
a final dividend
of 23 cents
per share 196,485,553 99.89 225,796 0.11 196,711,349 788
------------------------- ------------ ------- ----------- ------ ------------ ----------
3. To re-appoint
PricewaterhouseCoopers
LLP as auditors 196,099,742 99.69 610,679 0.31 196,710,421 1,717
------------------------- ------------ ------- ----------- ------ ------------ ----------
4.To authorise
the Audit Committee
to determine
the auditors'
remuneration 196,703,625 100.00 5,721 0.00 196,709,346 2,792
------------------------- ------------ ------- ----------- ------ ------------ ----------
5. To elect
Siggi Olafsson
as a director 195,815,999 99.55 894,642 0.45 196,710,641 1,497
------------------------- ------------ ------- ----------- ------ ------------ ----------
6. To re-elect
Said Darwazah
as a director 190,417,700 96.80 6,298,814 3.20 196,716,514 1,622
------------------------- ------------ ------- ----------- ------ ------------ ----------
7. To re-elect
Mazen Darwazah
as a director 193,925,828 98.58 2,783,900 1.42 196,709,728 2,410
------------------------- ------------ ------- ----------- ------ ------------ ----------
8. To re-elect
Robert Pickering
as a director 190,879,517 98.02 3,848,509 1.98 194,728,026 1,984,111
------------------------- ------------ ------- ----------- ------ ------------ ----------
9.To re-elect
Ali Al-Husry
as a director 195,245,623 99.26 1,464,293 0.74 196,709,916 2,222
------------------------- ------------ ------- ----------- ------ ------------ ----------
10. To re-elect
Patrick Butler
as a director 193,317,043 98.28 3,393,072 1.72 196,710,115 2,022
------------------------- ------------ ------- ----------- ------ ------------ ----------
11. To re-elect
Dr. Jochen
Gann as a director 195,107,616 99.19 1,602,499 0.81 196,710,115 2,022
------------------------- ------------ ------- ----------- ------ ------------ ----------
12. To re-elect
John Castellani
as a director 193,529,031 98.38 3,180,885 1.62 196,709,916 2,222
------------------------- ------------ ------- ----------- ------ ------------ ----------
13. To re-elect
Dr. Pamela
Kirby as a
director 190,289,183 96.74 6,421,682 3.26 196,710,865 1,272
------------------------- ------------ ------- ----------- ------ ------------ ----------
14. To re-elect
Nina Henderson
as a director 192,848,157 98.04 3,862,508 1.96 196,710,665 1,472
------------------------- ------------ ------- ----------- ------ ------------ ----------
15. To approve
the remuneration
report for
the year ended
31 December
2017 169,750,519 86.36 26,815,358 13.64 196,565,877 146,261
------------------------- ------------ ------- ----------- ------ ------------ ----------
16. To approve
and adopt the
2018 Management
Incentive Plan 195,620,834 99.45 1,088,481 0.55 196,709,315 2,822
------------------------- ------------ ------- ----------- ------ ------------ ----------
17. Authority
to allot shares 166,598,638 84.69 30,112,333 15.31 196,710,971 1,167
------------------------- ------------ ------- ----------- ------ ------------ ----------
18. To dis-apply
pre-emption
rights for
general purposes 196,660,802 99.97 50,469 0.03 196,711,271 867
------------------------- ------------ ------- ----------- ------ ------------ ----------
19. To dis-apply
pre-emption
rights for
an acquisition
or other capital
investment 195,530,359 99.40 1,179,711 0.60 196,710,070 2,067
------------------------- ------------ ------- ----------- ------ ------------ ----------
20. To authorise
the Company
to purchase
its own shares 195,989,881 99.68 621,703 0.32 196,611,584 100,553
------------------------- ------------ ------- ----------- ------ ------------ ----------
21. To authorise
the Company
to hold general
meetings on
no less than
14 clear days'
notice 187,831,722 95.49 8,878,028 4.51 196,709,750 2,388
------------------------- ------------ ------- ----------- ------ ------------ ----------
Declaration of final dividend
The dividend of 23 cents per share will be paid on 24 May 2018
to shareholders on the register on 6 April 2018. Shareholders who
are not resident in Jordan have been given the option of receiving
their dividend in Pounds Sterling. The exchange rate in respect of
this dividend will be $1.3521 to GBP1. The exchange rate for
Jordanian Dinar is fixed to the US Dollar at circa 1JD to
$1.41.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
Susan Ringdal
VP for Investor Relations and
Strategy +44 20 7399 2670
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
40 years, we've been creating high-quality medicines and making
them accessible to the people who need them. We're a global company
with a local presence across the United States (US), the Middle
East and North Africa (MENA) and Europe, and we use our unique
insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,500 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner in
the MENA region, and through our venture capital arm, are helping
bring innovative health technologies to people around the world.
For more information, please visit www.hikma.com.
LEI: 549300BNS685UXH4JI75
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGUWRURWRAVAAR
(END) Dow Jones Newswires
May 18, 2018 08:01 ET (12:01 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024